Adagene Inc. (ADAG): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADAG Stock Price Chart Interactive Chart >
ADAG Price/Volume Stats
| Current price | $2.80 | 52-week high | $20.98 |
| Prev. close | $2.82 | 52-week low | $2.68 |
| Day low | $2.68 | Volume | 29,100 |
| Day high | $2.90 | Avg. volume | 30,123 |
| 50-day MA | $3.55 | Dividend yield | N/A |
| 200-day MA | $8.68 | Market Cap | 122.62M |
Adagene Inc. (ADAG) Company Bio
Adagene Inc. operates as a biotechnology company. The Company focuses on the development of antibodies to cancer patients. Adagene serves patients in the United States and China.
Latest ADAG News From Around the Web
Below are the latest news stories about Adagene Inc that investors may wish to consider to help them evaluate ADAG as an investment opportunity.
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceSAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company’s management will participate in one-on-one investor meetings and provide a corporate update at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022. Details on the presentation include: SVB Leerink 11th Annual Global |
Adagene Announces Board and Management Appointments to Support Pipeline GrowthSAN DIEGO and SUZHOU, China, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced board and management appointments aimed at supporting the company’s pipeline growth and corporate development. The appointments include Liu Yuwen as a new independent board member and member of the Audit Committee, Jiping Zha, M.D., Ph.D. as Executive Vice President of Clinical Development, and Da |
Dosing underway in Adagene''s ADG106 + ADG116 study in solid tumorsAdagene (ADAG) announces that the first patient has been dosed in a combination cohort of ADG106 with ADG116, in patients with advanced/metastatic solid tumors.The dose escalation |
Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116SAN DIEGO and SUZHOU, China, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the first patient has been dosed in a combination cohort of its anti-CD137 agonist, ADG106, with its anti-CTLA-4 monoclonal antibody (mAb), ADG116, in patients with advanced/metastatic solid tumors. The dose escalation cohort will evaluate the safety and tolerability of this novel, proprieta |
Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development- SAN DIEGO and SUZHOU, China, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biotech company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the appointment of David Gandara, M.D., to its Scientific and Strate |
ADAG Price Returns
| 1-mo | -23.29% |
| 3-mo | -48.53% |
| 6-mo | -65.94% |
| 1-year | -80.25% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -65.30% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...